Thrombectomy Devices Market in U.S. Like to Reach $750.4 Million by 2025
Pune, Maharashtra, India, February 22 2021 (Wiredrelease) Allied Analytics –:The U.S. thrombectomy devices market is a relatively consolidated market with the presence of several large players and other mid-sized manufacturers, which have started developing different thrombectomy devices and still have their products in the pipeline. Stryker Corporation, Medtronic Plc., Penumbra, Inc., and Boston Scientific Corporation garnered the top most position in 2017, owing to increase in sales and availability of products, namely, Trevo (Stryker), Solitaire Revascularization Device (Medtronic Plc.), and others majorly the country.
According to a new report published by Allied Market Research, titled,”U.S. Thrombectomy Devices Market by Technology, Type. Disease and Utility: Opportunity Analysis and Industry Forecast, 2018 – 2025,”the U.S. thrombectomy devices market was valued at $501.9 million in 2017, and is projected to reach $750.4 million by 2025, growing at a CAGR of 5.1 % from 2018 to 2025. The mechanical thrombectomy devices used for peripheral and coronary disorders garner major shares of the market, and are expected to maintain this trend during the forecast period.
Click Here To Access Sample Report @ https://www.alliedmarketresearch.com/request-sample/5195
High prevalence of AMI, PAD, DVT, and PE, owing to sedentary and unhealthy lifestyle majorly drives the growth of the U.S. thrombectomy devices market. In addition, need for sophisticated healthcare infrastructure and increase in demand for minimally invasive treatments fuel the growth of the market. Moreover, rise in geriatric population, which increases incidence of cardiovascular diseases, and growth in competition among key players, which results in technological advancements and innovations significantly contribute toward the growth of the market. However, dearth of trained professionals, lack of awareness, and complicated use of thrombectomy devices restrain the market growth.
By technology, the thrombectomy devices market is categorized into mechanical, aspiration, and rheolytic thrombectomy devices. The mechanical thrombectomy devices segment is anticipated to dominate the market during the forecast period, due to increase in incidence of acute ischemic strokes, peripheral artery diseases, periphery embolism, and deep vein thrombosis, which prevail in blood vessels.
The use of thrombectomy devices for the treatment of neural disorders spearheaded the market in 2017, and trend is expected to continue throughout the forecast period. The manual thrombectomy devices segment was the highest revenue generator in 2017, due to ease of operating a manual thrombectomy device.
The disposable thrombectomy devices segment generated the highest revenue in 2017, and is expected to continue this trend throughout the analysis period, due to the fact that disposable devices reduce the chances of contamination and severity of in-hospitalization diseases. However, the reusable thrombectomy devices segment is anticipated to witness considerable growth in the near future, registering a CAGR of 6.9%, owing to advancements in the technology.
The key players profiled in this report include Boston Scientific Corporation, Medtronic Plc, Teleflex Incorporated, Penumbra Inc., Koninklijke Philips N.V., AngioDynamics, Inc., Terumo Corporation, Johnson and Johnson, Stryker Corporation, and Capture Vascular, Inc. The other players considered in the value chain analysis (but not in the report) include, Argon Medical Devices, Inc., Inari Medical, Inc., and others.
For Purchase Enquiry: @ https://www.alliedmarketresearch.com/purchase-enquiry/5195
Key Findings of theU.S. Thrombectomy Devices Market:
In 2017, the mechanical thrombectomy devices segment generated the highest revenue, and is anticipated to dominate the market throughout the forecast period.
The peripheral thrombectomy devices segment is anticipated to grow at the highest rate from 2018 to 2025.
The disposable thrombectomy devices segment is anticipated to generate the highest revenue in 2025.
The automated thrombectomy devices is anticipated to register a CAGR of 6.9% from 2018 to 2025.
This content has been published by Allied Analytics company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at email@example.com.